

## BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors.  
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Tomoo Iwakuma	POSITION TITLE Assistant Professor, Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA		
eRA COMMONS USER NAME TIWAKU			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing,</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Kyushu University, Fukuoka, Japan	M.D.	1991	Medicine
Kyushu University, Fukuoka, Japan	Residency	1991	Orthopedics
Beppu Developmental Medical Center, Japan	Residency	1992	Orthopedics
Kyushu University, Fukuoka, Japan	Ph.D.	1997	Biochemistry
University of Alberta, Alberta, Canada	Post-doct.	1997	Gene Therapy
University of Florida, Florida	Post-doct.	1998	Virology
Baylor College of Medicine, Texas	Res. assoc.	1999	Pharmacology
MD Anderson Cancer Center, Texas	Post-doct.	2000	Molecular Genetics

Please refer to the application instructions in order to complete sections A, B, and C of the Biographical Sketch.

### **A. Positions and Honors** **Positions and Employment**

06/1991 – 06/1992: **Residency**, Department of Orthopedics, Kyushu University in Japan.  
06/1992 – 03/1993: **Residency**, Beppu Developmental Medical Center in Japan.  
04/1997 – 01/1998: **Postdoctoral fellow**, Department of Medical Microbiology and Immunology,  
University of Alberta in Canada.  
01/1998 – 01/1999: **Postdoctoral fellow**, Department of Molecular Genetics and Microbiology and  
Gene Therapy Center, University of Florida.  
01/1999 – 06/2000: **Research associate**, Department of Pharmacology, Baylor College of Medicine.  
06/2000 – 06/2003: **Postdoctoral fellow**, Department of Molecular Genetics, Cancer Genetics,  
The University of Texas MD Anderson Cancer Center.  
06/2003 – 08/2005: **Instructor** at the Department of Molecular Genetics, Cancer Genetics,  
The University of Texas MD Anderson Cancer Center.  
08/2005 – present: **Assistant professor**, Department of Genetics/Stanley S. Scott Cancer Center,  
Louisiana State University Health Sciences Center, New Orleans, LA.

### **Other Experience and Professional Memberships**

#### **Membership**

1991: Japanese Orthopedics Society  
2005: Member, American Associate of Cancer Research (Active member: 88899)  
2007: Metastasis Research Society

#### **Patent**

WO/1999/061598, LENTIVIRAL VECTOR COMPOSITIONS AND METHODS OF USE, Inventors (CHANG,  
Lung-Ji, Cui, Yan, and **Iwakuma, Tomoo**)

### **Awards and Honors**

1. April, 2003; Research Poster Achievement Award, Spring retreat, The Genes and Development program, The University of Texas, MD Anderson Cancer Center
2. March 14, 2008; Research Enhancement Fund (REF) 410-16-9101 (Iwakuma).
3. March 28, 2009; Research achievement award, LCRC Retreat.

## B. BIBLIOGRAPHY

1. **Iwakuma T**, Chuman K, Iwamoto Y, Tanaka, K, Sugioka Y. Renal toxicity of chemotherapy for bone and soft tissue sarcoma. (Japanese) **J. of West Jap. Soc. Orthopedic and Traumatology** **1992**, 41 (2), 512-515.
2. **Iwakuma T**, Chuman K, Iwamoto Y, Tanaka, K, Oomiya K, Sugioka Y. Effect of granulocyte colony stimulating factor (G-CSF) on myelosuppression due to chemotherapy for malignant bone and soft tissue tumors. (Japanese) **J. of West Jap. Soc. Orthopedic and Traumatology** **1993**, 42 (1), 429-431.
3. Oga M, Mashima T, **Iwakuma T**, Sugioka Y. Dysphagia complications in ankylosing spinal hyperostosis and ossification of the posterior longitudinal ligament. Roentgenographic findings of the developmental process of cervical osteophytes causing dysphagia. **Spine** **1993**, 18 (3): 391-394.
4. Tsuzuki T, Sakumi K, Shiraishi A, Kawate H, Igarashi H, **Iwakuma T**, Tominaga Y, Zhang S, Shimizu S, Ishikawa T, Sekiguchi M. Targeted disruption of the DNA repair methyltransferase gene renders mice hypersensitive to alkylating agent. **Carcinogenesis** **1996**, 17 (6): 1215-1220.
5. **Iwakuma T**, Shiraishi A, Fukuhara M, Kawate H, Sekiguchi M. Organization and expression of the mouse gene for DNA repair methyltransferase. **DNA Cell. Biol.** **1996**, 15 (10): 863-872.
6. Tanaka K, **Iwakuma T**, Harimaya K, Sato H, Iwamoto Y. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. **J. Clin. Invest.** **1997**, 99 (2): 239-247.
7. **Iwakuma T**, Sakumi K, Nakatsuru Y, Kawate H, Igarashi H, Shiraishi A, Tsuzuki T, Ishikawa T, Sekiguchi M. High incidence of nitrosamine-induced tumorigenesis in mice lacking DNA repair methyltransferase. **Carcinogenesis** **1997**, 18 (8): 1631-1635.
8. Tsuzuki T, Kawate H, **Iwakuma T**. Study on carcinogenesis and mutation suppression: repair of alkylation DNA damage and suppression of tumors. (Japanese) **Fukuoka Igaku Zasshi** **1998**, 89 (1): 1-10. Review.
9. Chang L-J, Urlacher V, **Iwakuma T**, Cui Y, Zucali J. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system. **Gene Therapy** **1999**, 6 (5): 715-728.
10. Cui Y, **Iwakuma T**, Chang L-Ji. Contributions of viral splice sites and cis-regulatory elements to lentivirus vector function. **J Virol.** **1999**, 73 (7): 6171-6176.
11. **Iwakuma T**, Cui Y., Chang L-Ji. Self-Inactivating lentiviral vectors with U3 and U5 modifications. **Virology** **1999**, 261 (1): 120-132.
12. Zhu K, Henning D, **Iwakuma T**, Valdez BC, Busch H. Adriamycin inhibits human RH II/Gu RNA helicase activity by binding to its substrate. **Biochem. Biophys. Res. Commun.** **1999**, 266 (2): 361-365.
13. Tsuzuki T, Egashira A, Igarashi H, **Iwakuma T**, Nakatsuru Y, Tominaga Y, Kawate H, Nakao K, Nakamura K, Ide F, Kura S, Nakabeppu Y, Katsuki M, Ishikawa T, Sekiguchi M. Spontaneous tumorigenesis in mice defective in the MTH1 gene encoding 8-oxo-dGTPase. **Proc. Natl. Acad. Sci. USA** **2001**, 98 (20): 11456-11461.

14. **Iwakuma T**, Lozano G. Mdm2, an Introduction. **Mol. Cancer Res.** **2003**, 1 (14): 993-1000. Review.
15. **Iwakuma T**, Parant JM, Fasulo Jr M, Zwart E, Jacks T, de Vries A, Lozano G. Mutation at p53 serine 389 does not rescue the embryonic lethality in *mdm2* or *mdm4* null mice. **Oncogene** **2004**, 23 (46): 7644-7650.
16. Bruins W., Zwart E., Attardi LD, **Iwakuma T**, Hoogervorst EM, Beems RB, Miranda B, van Oostrom CTM, van den Berg J, van den Aardweg G, Lozano G, van Steeg H, Jacks T, de Vries A. Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. **Mol. Cell. Biol.** **2004**, 24 (20): 8884-8894.
17. **Iwakuma T\***, Lang GA\*, Suh A-Y, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G. Gain of Function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. **Cell** **2004**, 119 (6): 861-872. \*These two authors contributed equally to this study.
18. **Iwakuma T.\*** Li-Fraumeni syndrome model mouse by a gain-of-function mutant p53. (Japanese) **Experimental Medicine** **2005**, 23 (5): 746-749. Current Topics.
19. **Iwakuma T**, Lozano G, Flores ER. Li-Fraumeni Syndrome: a p53 Family Affair. **Cell Cycle** **2005**, 4 (7): 41 - 43. Extra-Views.
20. **Iwakuma T**, Lozano G. Crippling p53 activities via knockin mutations in mouse models. **Oncogene** **2007**, 2177-2184. Review.
21. **Iwakuma T\***, Tochigi Y, Van Pelt CS, Caldwell LC, Terzian T, Parant JM, Chau GP, Koch J, Eischen CM, Lozano G.\*. *Mtbp* haploinsufficiency in mice increases tumor metastasis. **Oncogene** **2008**, 27(13):1813-1820. \*Co-corresponding authors.
22. Terzian T, Suh Y-A, **Iwakuma T**, Post SM, Neumann M, Lang GA, Van Pelt CS, Lozano G. The inherent instability of mutant p53 is alleviated by *Mdm2* or *p16<sup>INK4a</sup>* loss. **Genes & Development** **2008**, 22(10): 1337-1344.
23. Barboza JA, **Iwakuma T**, Terzian T., El-Naggar AK, Lozano G. Mdm2 and Mdm4 loss regulates distinct p53 activities. **Molecular Cancer Res.** **2008**, 6(6): 947-954.
24. Busso CS, **Iwakuma T**, Izumi T. Ubiquitination of mammalian AP endonuclease (APE1) regulated by the p53-MDM2 signaling pathway. **Oncogene** **2009**, 28(13):1616-1625.
25. Adhikari A, **Iwakuma T\***. Mutant p53 gain of oncogenic function: *in vivo* evidence, mechanism of action and its clinical implications. **Fukuoka Acta Medica** **2009**. In press.